Although several biomarkers have been studied with these purposes, none are currently validated for early HCC detection, prognosis assessment, and prediction of response to systemic therapies, with the exception of serum AFP, that helps to select patients who will benefit from ramucirumab [20]. This evidence concerns the gene AFP and hepatocellular carcinoma.